ABSTRACT
BACKGROUND: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with chronic kidney disease (CKD) and could be related to oxidative stress. Vascular calcification (VC) has been established as a critical risk factor for accelerated CVD. In CKD, phosphorus (Pi), iron (Fe) and Nrf2 are modulators of VC and important agonists and antagonists of oxidative stress. The aim of this study was to determine whether Fe administration, which is commonly used to treat renal anemia, affects aortic Fe overload and VC, and whether Nrf2 and its related genes, ferritin H and HIF-1α, are involved in the development of VC. METHODS: A CKD model was created in rats by administering adenine and simultaneously feeding a high-Pi diet. In addition to control and CKD rats without Fe administration (No-Fe group), Fe was administered orally (PO-Fe group) or intraperitoneally (IP-Fe group) to CKD animals to clarify the effects of Fe administration on the aortic Fe and calcium (Ca) contents and the involvement of Nrf2 and its induced antioxidative proteins, ferritin H and HIF-1α, in VC. RESULTS: The aortic Fe content increased significantly in the IP-Fe group, which was closely correlated with liver HAMP (hepcidin) expression in all animals. Fe administration had no significant effect on the aortic Ca and Pi contents regardless of the route of Fe administration. The aortic mRNA level of Nrf2 was significantly increased in the IP-Fe group and correlated with serum Pi levels and aortic Fe contents, which could respond to oxidative stress. Notably, the mRNA level of Nrf2 was also significantly correlated with the mRNA levels of ferritin H and HIF-1α. Since we could not measure Nrf2 protein levels in this study, we confirmed the upregulation of HMOX1 and NQO1 mRNA expression in parallel with Nrf2 mRNA. CONCLUSION: Parenteral Fe administration increased aortic Fe in parallel with the liver HAMP mRNA level but did not affect VC. Aortic Nrf2 mRNA levels correlated significantly with aortic Fe and serum Pi levels and with aortic mRNA levels of ferritin H and HIF-1α as well as HMOX1 and NQO1.
Subject(s)
Cardiovascular Diseases , Renal Insufficiency, Chronic , Vascular Calcification , Humans , Rats , Animals , Iron/metabolism , Phosphorus , NF-E2-Related Factor 2/metabolism , Renal Insufficiency, Chronic/drug therapy , Renal Insufficiency, Chronic/complications , Ferritins , Calcium/metabolism , Vascular Calcification/drug therapy , Vascular Calcification/etiology , Cardiovascular Diseases/complications , RNA, MessengerABSTRACT
BACKGROUND: TAFRO syndrome is an acute or subacute systemic inflammatory disease with no apparent cause, presenting with fever, generalized edema, thrombocytopenia, renal damage, anemia, and organ enlargement. Interleukin-6, vascular endothelial growth factor, and other cytokines are thought to be the etiologic agents that increase vascular permeability and cause the resulting organ damage. Only few reports of renal biopsy performed in patients with TAFRO syndrome exist. CASE PRESENTATION: A 61-year-old woman, with a history of Sjogren's syndrome, was admitted to our hospital with anasarca and abdominal distension. Based on the clinical course and various laboratory findings, we diagnosed TAFRO syndrome. Renal biopsy revealed thrombotic microangiopathy, including endothelial cell swelling, subendothelial space expansion, and mesangiolysis. She was treated with oral prednisolone and cyclosporine, with consequent resolution of anasarca, pleural effusion, and ascites, and improvement in renal function and urinary findings. The patient's platelet count also normalized after 2 months of treatment. CONCLUSIONS: Given that only few reports of improvement in the systemic symptoms of TAFRO syndrome using steroids and cyclosporine exist, our study investigating the relationship between the pathogenesis of TAFRO syndrome and renal disorders, as well as treatment methods, provides valuable insights.
Subject(s)
Kidney Diseases , Thrombotic Microangiopathies , Biopsy/adverse effects , Castleman Disease , Cyclosporine/therapeutic use , Edema/drug therapy , Edema/etiology , Female , Humans , Kidney Diseases/pathology , Middle Aged , Steroids/therapeutic use , Thrombotic Microangiopathies/drug therapy , Vascular Endothelial Growth Factor A/metabolismABSTRACT
BACKGROUND: Decreased erythropoietin levels and impaired iron metabolism due to excessive hepcidin levels are responsible for renal anaemia in patients undergoing haemodialysis. Recently, erythroferrone (ERFE) has been identified as a factor that regulates hepcidin. In addition, fibroblast growth factor 23 (FGF23), which has been recognized as a phosphorus-regulating hormone, appears to be involved in haematopoietic regulation. Clarification of the detailed mechanism of haematopoiesis could lead to the improvement of renal anaemia treatment. METHODS: Epoetin beta pegol (CERA) was administered to patients undergoing haemodialysis at week 0, and the same amount of CERA with saccharated ferric oxide (SFO) was administered at week 4. The changes in haematopoiesis-related biomarkers, including ERFE, intact FGF23 (iFGF23), C-terminal FGF23 (cFGF23), and inflammatory markers, were examined. RESULTS: Administration of CERA increased ERFE levels, decreased hepcidin levels, and stimulated iron usage for haematopoiesis, leading to an increase in reticulocytes (Ret) and haemoglobin (Hb). Simultaneous administration of SFO with CERA (CERA + SFO) significantly attenuated the responses of ERFE, Ret, and Hb compared with CERA alone. Although iFGF23 levels were not affected by either CERA or CERA + SFO, cFGF23 was significantly elevated from baseline after CERA. Since cFGF23 levels were not affected by CERA + SFO, cFGF23 levels after CERA + SFO were significantly lower than those after CERA alone. The ratio of iFGF23 to cFGF23 (i/cFGF23 ratio) was significantly higher after CERA + SFO than that after CERA alone. In addition, high-sensitivity C-reactive protein (hsCRP) levels were significantly higher after CERA + SFO than after CERA alone. CONCLUSION: Administration of SFO suppressed haematopoietic responses induced by CERA. Elevation of i/cFGF23 ratio and hsCRP could account for the inhibitory effects of SFO on haematopoiesis. TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network (ID UMIN000016552 ).
Subject(s)
Erythropoiesis/drug effects , Erythropoietin/therapeutic use , Ferric Oxide, Saccharated/pharmacology , Fibroblast Growth Factor-23/metabolism , Polyethylene Glycols/therapeutic use , Renal Insufficiency, Chronic/blood , Aged , Anemia/drug therapy , Anemia/metabolism , Biomarkers/blood , Biomarkers/metabolism , Female , Ferric Oxide, Saccharated/adverse effects , Fibroblast Growth Factor-23/blood , Humans , Iron/metabolism , Male , Peptide Hormones/metabolism , Renal Dialysis , Renal Insufficiency, Chronic/therapyABSTRACT
OBJECTIVE: Iron administration affects serum levels of intact (I-) fibroblast growth factor-23 (FGF23) and its cleavage product C-terminal (C-) FGF23 in iron-deficient patients on maintenance hemodialysis (MHD). The objective of this study was to compare the effect of oral or intravenous iron administration on serum levels of I-FGF23 and C-FGF23 in iron-deficient patients on MHD. DESIGN AND METHODS: A prospective randomized study. SUBJECTS: Participants on MHD with severe iron deficiency (n = 61). INTERVENTION: Participants were randomized to receive oral iron (50 mg of sodium ferrous citrate daily; oral group, n = 29) or intravenous iron (40 mg of saccharated ferric oxide weekly; IV group, n = 32). MAIN OUTCOME MEASURE: Changes in I-FGF23 and C-FGF23 after 10 weeks of treatment. RESULTS: Iron supplementation significantly increased hemoglobin, mean corpuscular volume, ferritin, and transferrin saturation rate, and decreased erythropoiesis-stimulating agent dose and erythropoiesis-stimulating agent resistance index value. Serum phosphate, calcium, and intact parathyroid hormone levels did not change significantly during the study. I-FGF23 levels increased significantly in the IV group and did not change in the oral group, whereas C-FGF23 levels were significantly reduced in both groups. Serum interleukin-6 and tumor necrosis factor-α levels were increased in both groups. Multiple regression analysis indicated the relationship between iron or erythropoiesis and FGF23 metabolism. CONCLUSION: Iron administration to patients on MHD with severe iron deficiency decreased C-FGF23 levels, whereas intravenous iron increased I-FGF23 levels though oral iron did not. If the target of chronic kidney disease-mineral and bone disorder therapy is reducing I-FGF23 levels, we suggest the use of oral iron.
Subject(s)
Anemia, Iron-Deficiency/drug therapy , Ferric Oxide, Saccharated/therapeutic use , Ferrous Compounds/therapeutic use , Fibroblast Growth Factors/metabolism , Renal Dialysis , Renal Insufficiency, Chronic/complications , Administration, Intravenous , Administration, Oral , Aged , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/complications , Citric Acid , Dietary Supplements , Female , Ferric Oxide, Saccharated/administration & dosage , Ferric Oxide, Saccharated/blood , Ferrous Compounds/administration & dosage , Ferrous Compounds/blood , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/blood , Fibroblast Growth Factors/drug effects , Humans , Male , Prospective Studies , Renal Insufficiency, Chronic/therapy , Treatment OutcomeABSTRACT
We compared the effects on the nutritional condition and health-related quality of life (HR-QoL) of the treatment of patients with on-line hemodiafiltration (OL-HDF) and conventional hemodialysis (CHD) using a superflux dialyzer. In total, 47 maintenance (M) HD patients were treated by CHD with a high-flux dialyzer for the first 4 months (1st CHD) and were then switched to predilution OL-HDF for the next 4 months (OL-HDF), after which CHD was resumed for the last 4 months (2nd CHD). We assessed the clinical parameters, fat mass value, muscle mass value, and HR-QoL. In patients with low serum albumin levels, these levels significantly (p < 0.05) increased in the OL-HDF period. Moreover, the fat mass values significantly (p < 0.05) increased in patients with decreased fat mass values in the OL-HDF period. Although there was no significant difference in the patients with higher scores of physical functioning, role physical, vitality, and social functioning, patients with lower scores in the 1st CHD period had significantly increased (p < 0.05) in the OL-HDF period. In this crossover study, we revealed that OL-HDF treatment significantly improved the nutritional conditions and HR-QoL scores compared with the improvement observed after CHD with a superflux dialyzer, especially for maintenance hemodialysis patients with malnutrition and a low QoL.
Subject(s)
Hemodiafiltration , Kidney Failure, Chronic , Cross-Over Studies , Humans , Kidney Failure, Chronic/therapy , Quality of Life , Renal Dialysis/adverse effectsABSTRACT
PURPOSE: Previous studies reported that the long-acting erythropoiesis-stimulating agent (ESA) significantly suppresses the expression of hepcidin, which regulates iron availability. In this study, we compared the iron availability for erythropoiesis between short and long-acting ESA over a long period. METHODS: We enrolled 69 hemodialysis patients in this study. All patients were treated with short-acting ESA (epoetin-α or epoetin-ß) for the first 30 months. Then, all patients switched to long-acting ESA (continuous erythropoietin receptor activator-methoxy polyethylene glycol-epoetin beta) for the next 30 months. We measured their blood levels of Hb, ferritin, iron, total iron-binding capacity, intact-parathyroid hormone, calcium, phosphate, albumin, and highly sensitive CRP level. RESULTS: There was no significant change in the dose of short or long-acting ESA during the study period. Compared with the short-acting ESA period, the mean hemoglobin (Hb) and transferrin saturation levels were significantly increased in the long-acting ESA period (from 10.3 ± 0.2 to 10.6 ± 0.3 g/dL). On the other hand, the mean serum ferritin level (from 72 ± 22.2 to 56.3 ± 14 ng/mL) and the dose of IV iron (from 108 ± 63 to 53 ± 27 mg/month) were significantly decreased in the long-acting ESA period. CONCLUSION: In this study, we found that anemia treatment with long-acting ESA attenuated the iron utilization for erythropoiesis and maintained target Hb levels without requiring a higher dose of IV iron or ESA.
Subject(s)
Anemia , Erythropoietin , Hematinics , Anemia/drug therapy , Anemia/etiology , Erythropoiesis , Erythropoietin/pharmacology , Erythropoietin/therapeutic use , Ferritins , Hematinics/pharmacology , Hematinics/therapeutic use , Hemoglobins/metabolism , Humans , Iron/metabolism , Renal Dialysis/adverse effectsABSTRACT
INTRODUCTION: Although several investigators have reported the relationship between bone mineral density (BMD) and mortality in patients on hemodialysis, it is unclear BMD of which site is most strongly associated with mortality. METHODS: We examined the factors related to fractures in patients on hemodialysis in 2009. Based on these data, we investigated the influence of BMD of different sites on mortality in this cohort of 81 patients on hemodialysis. BMD was measured at the distal third of the radius (1/3 Rad), lumbar spine, and total hip. Fifteen patients had prevalent vertebral fractures and seven had prevalent hip fractures. The influences of age, body mass index (BMI), serum creatinine (Cr), serum albumin (Alb), dialysis vintage, and parathyroid hormone (PTH, measured as whole PTH) on mortality were also studied. RESULTS: Fifty-two patients died by August 31, 2018. BMD was significantly higher in the survival group than in the deceased group only for the 1/3 Rad group (P < .001). Although patients with prevalent hip or vertebral fractures showed a higher mortality rate than those without fractures, no significant difference was observed. In the deceased group, age was significantly higher, and BMI and Cr levels were significantly lower than those in the survival group (P < .001, P < .05, and P < .01; respectively). After adjustment for these parameters, BMD of the 1/3 Rad remained a significant prognostic factor. CONCLUSION: Although this was a study with a limited number of patients, BMD of the 1/3 Rad appears to be associated with mortality in patients on hemodialysis.